环氧化酶-2、Fas及Fas配体在肺腺癌和非典型腺瘤样增生中的表达

Expression of cyclooxygenase-2, Fas and Fas ligand in pulmonary adenocarcinoma and atypical adenomatous hyperplasia.

作者信息

Takigawa Nagio, Ida Mikiko, Segawa Yoshihiko, Nakata Masao, Mandai Koichi, Kishino Daizo, Fujiwara Keiichi, Saeki Hideyuki, Takashima Shigemitsu, Eguchi Kenji

机构信息

Department of Internal Medicine, National Shikoku Cancer Center Hospital, 13 Horinouchi, Matsuyama 790-0007, Japan.

出版信息

Anticancer Res. 2003 Nov-Dec;23(6D):5069-73.

PMID:14981968

Abstract

BACKGROUND

Atypical adenomatous hyperplasia (AAH) has been reported to be a precancerous lesion of pulmonary adenocarcinoma. Cyclooxygenase-2 (COX-2), Fas and Fas ligand (FasL) are believed to be involved in the pathogenesis and progression of cancer.

PATIENTS AND METHODS

We examined the expression of COX-2, Fas and FasL in 31 tissue specimens of adenocarcinoma and 9 of AAH using an immunohistochemical method.

RESULTS

COX-2 staining was observed in 20 (65%) specimens of adenocarcinoma and 2 (22%) of AAH. There was a significant difference in incidence of expression between these two groups (p = 0.025). All tumor specimens obtained from three patients with simultaneous multiple adenocarcinoma showed positive COX-2 staining. In two patients having both adenocarcinoma and AAH, COX-2 expression was detected in adenocarcinoma but not in AAH. Fas was expressed in 5 (16%) adenocarcinoma and 2 (22%) AAH specimens. FasL was detected in 3 (9.7%) adenocarcinoma and 1 (11%) AAH specimen.

CONCLUSION

These findings suggest that COX-2 might play a role in the progression from AAH to adenocarcinoma.

摘要

背景

非典型腺瘤样增生（AAH）据报道是肺腺癌的一种癌前病变。环氧合酶-2（COX-2）、Fas和Fas配体（FasL）被认为参与癌症的发病机制和进展。

患者和方法

我们采用免疫组织化学方法检测了31例腺癌组织标本和9例AAH组织标本中COX-2、Fas和FasL的表达。

结果

在20例（65%）腺癌标本和2例（22%）AAH标本中观察到COX-2染色。两组之间的表达发生率有显著差异（p = 0.025）。从3例同时患有多发性腺癌的患者获得的所有肿瘤标本均显示COX-2染色阳性。在2例同时患有腺癌和AAH的患者中，在腺癌中检测到COX-2表达，但在AAH中未检测到。Fas在5例（16%）腺癌和2例（22%）AAH标本中表达。FasL在3例（9.7%）腺癌和1例（11%）AAH标本中检测到。